{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:38:48Z","timestamp":1775248728486,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.cardfail.2018.04.010","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T06:11:55Z","timestamp":1525673515000},"page":"533-536","source":"Crossref","is-referenced-by-count":21,"title":["Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database"],"prefix":"10.1016","volume":"24","author":[{"given":"Amichai","family":"Perlman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruria","family":"Hirsh Raccah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2018.04.010_bib0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0015","article-title":"The safety of sacubitril-valsartan for the treatment of chronic heart failure","volume":"16","author":"Tyler","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4330\/wjc.v9.i7.594","article-title":"Is Entresto good for the brain?","volume":"9","author":"Patel","year":"2017","journal-title":"World J Cardiol"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2005.03.010","article-title":"Metabolism of amyloid-\u03b2 peptide and Alzheimer's disease","volume":"108","author":"Iwata","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.taap.2017.03.014","article-title":"The effect of angiotensin receptor neprilysin inhibitor, sacubitril\/valsartan, on central nervous system amyloid-\u03b2 concentrations and clearance in the cynomolgus monkey","volume":"323","author":"Schoenfeld","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0035","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-\u03b2 concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"Langenickel","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0040","author":"Center for Drug Evaluation and Research"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.687","article-title":"Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction","volume":"19","author":"Cannon","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0055","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0060","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.12611","article-title":"Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration Adverse Event Reporting System","author":"Raschi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0065","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cardfail.2018.04.010_bib0075","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2017.5150","article-title":"Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010","volume":"317","author":"Downing","year":"2017","journal-title":"JAMA"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916418301738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916418301738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T22:50:34Z","timestamp":1536792634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916418301738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1071916418301738"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2018.04.010","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}